Article Text

Download PDFPDF
Upregulation of lymphotoxin β expression in liver progenitor (oval) cells in chronic hepatitis C
  1. K N Lowes1,
  2. E J Croager2,
  3. L J Abraham2,
  4. J K Olynyk3,
  5. G C T Yeoh2
  1. 1Biochemistry and Molecular Biology, School of Biomedical and Chemical Sciences, The University of Western Australia, Crawley 6009, Australia, and School of Medicine and Pharmacology, The University of Western Australia at Fremantle Hospital, Fremantle 6160, Australia
  2. 2Western Australian Institute for Medical Research and Centre for Medical Research, and Biochemistry and Molecular Biology, School of Biomedical and Chemical Sciences, The University of Western Australia, Crawley 6009, Australia
  3. 3Western Australian Institute for Medical Research and Centre for Medical Research, The University of Western Australia, Crawley 6009, Australia, and School of Medicine and Pharmacology, The University of Western Australia at Fremantle Hospital, Fremantle 6160, Australia
  1. Correspondence to:
    Associate Professor G C T Yeoh, Biochemistry and Molecular Biology, School of Biomedical and Chemical Sciences, The University of Western Australia, Crawley 6009, Western Australia;
    yeoh{at}cyllene.uwa.edu.au

Abstract

Background: Bipotent liver progenitor (oval) cells with the ability to differentiate into hepatocytes and biliary epithelium have recently been identified in human subjects with hepatitis C. Animal studies suggest that members of the tumour necrosis factor family, including lymphotoxin β (LT-β), regulate oval cell proliferation in liver disease, but its role in human liver disease is unclear.

Aims: This study seeks to establish a role for LT-β in hepatitis C related liver injury and to provide evidence that its increased expression is related to the presence of oval cells.

Methods: Liver biopsy specimens were obtained from patients with chronic hepatitis C virus (HCV) infection (n=20). Control liver samples (n=5) were obtained from liver resection or transplant surgery. LT-β expression in liver biopsy specimens was studied using quantitative real time polymerase chain reaction and immunohistochemistry.

Results: LT-β mRNA levels were similar in control and HCV liver in the absence of fibrosis. In subjects with portal fibrosis, LT-β mRNA levels were elevated 2.2-fold over control liver levels (p=0.04). In subjects with bridging fibrosis, LT-β mRNA levels increased 4.4-fold over control liver levels (p=0.02). LT-β mRNA levels in subjects with established cirrhosis were increased 3.3-fold compared with controls and 2.6-fold compared with mild liver damage (p=0.02). Immunohistochemical analysis established that LT-β was expressed by oval cells, inflammatory cells, and small portal hepatocytes.

Conclusions: In chronic HCV infection, LT-β expression is observed in multiple hepatic cell types, including oval cells. LT-β expression is significantly increased when fibrosis or cirrhosis is present, suggesting a role for LT-β in the pathogenesis of chronic hepatitis C and a possible role in oval cell mediated liver regeneration.

  • oval cell
  • liver
  • fibrosis
  • tumour necrosis factor
  • HCV, hepatitis C virus
  • HCC, hepatocellular carcinoma
  • TNF, tumour necrosis factor
  • TNFRI, tumour necrosis factor receptor 1
  • LT, lymphotoxin
  • LT-βR, LT-β receptor
  • NFκB, nuclear factor κB
  • CDE, choline deficient ethionine supplemented
  • PCR, polymerase chain reaction
  • GAPDH, glyceraldehyde-3-phosphate dehydrogenase
  • M2-PK, M2-pyruvate kinase
  • GST, glutathione S-transferase
  • LCA, leucocyte common antigen
  • PCNA, proliferating cell nuclear antigen

Statistics from Altmetric.com

Request Permissions

If you wish to reuse any or all of this article please use the link below which will take you to the Copyright Clearance Center’s RightsLink service. You will be able to get a quick price and instant permission to reuse the content in many different ways.

Footnotes